different kidney diseases being targeted so got to be cautious about comparing , but this asset (68% proteinurya reduction against placebo which is huge!) and the Novartis news yesterday that Fabhalta got fda accelerated approval for Iga nepropathy, 38% reduction proteinuria vs placebo just serves to highlight imo the relatively small effect of the dimx asset as a protein in urine reducer (17% vs placebo in phase 2).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
58.5¢ |
Change
0.010(1.74%) |
Mkt cap ! $346.8M | |||
| Open | High | Low | Value | Volume |
| 58.0¢ | 59.5¢ | 56.0¢ | $887.0K | 1.514M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 334480 | 58.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 59.0¢ | 5084 | 1 |
View Market Depth
| Last trade - 16.10pm 01/07/2025 (20 minute delay) ? |
| DXB (ASX) Chart |